1 September 2021 - Nat-Lenalidomide expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes.
Natco Pharma (Canada) announced today the launch of Nat-Lenalidomide capsules, the first generic alternative to Revlimid to be approved by Health Canada.